IP — International Paper Company

Sentiment is mixed-to-cautious. Q2 2026 revenue of $6.004B missed and Q2 free cash flow was -$7M, which weighed on the stock; however, adjusted EBITDA was still $587M, the dividend remains $0.4625/quarter, and the dataset shows a Buy consensus with an average price target near $50. The market is waiting for actual cash-flow and margin proof before turning more bullish.

Revenue stepped up structurally in 2025 after the DS Smith acquisition — from roughly $4.6B/quarter in 2024 to roughly $6.0B/quarter — but has since flattened and turned slightly negative: Q2 2026 revenue fell 11.3% YoY to $6.004B from $6.767B. Reported operating margins collapsed in Q3/Q4 2025 (-$426M and -$2.565B operating income) almost entirely due to impairments/write-downs; excluding those, underlying operations are barely above breakeven, with Q1 2026 operating margin of 2.9% and Q2 2026 of 0.7%. This is a cyclical/restructuring trough, not a clean growth story.

Trailing valuation is not meaningful because TTM EPS is -$6.49, putting P/E at -6.1x. On forward consensus EPS of ~$1.37, the stock trades around 29x forward earnings — richer than IP's 5-year average P/E of 24.0x. Price-to-sales of 0.87x is roughly in line with the 5-year average of 0.81x, and price-to-book is 1.46x. Bottom line: valuation is fair-to-rich on current estimates and relies on a meaningful earnings recovery to look cheap.

At $39.88, the market is paying ~29x consensus EPS of $1.37 — that is a recovery multiple, not a distressed-asset price. If containerboard price hikes and DS Smith synergies push EPS toward $2.00, the multiple drops to roughly 20x and the stock looks reasonable; if earnings stay near breakeven, the stock is expensive. This is a bet on cyclical recovery and execution, not a classic value-on-trailing-earnings setup.

As of 2026-08-27, RSI was 47.0 — neutral, not oversold or overbought. The stock sat 2.9% below its 20-day SMA, 1.0% above its 50-day SMA, and 3.9% above its 200-day SMA, implying a range-bound consolidation within the $29.26–$50.25 52-week range. There is no clear momentum trigger; a close back above the ~$41 SMA20/previous-close area would improve near-term tone, while losing the ~$39.50 SMA50 would weaken it.

• North American containerboard supply/demand and pricing: tighter supply and announced price increases are the main swing factor for IP's recovery.
• Interest rates and financing costs: IP is capital-intensive with $8.2B in long-term debt; higher-for-longer rates pressure capex-heavy restructuring and mill investments.
• Industrial production and e-commerce packaging demand: corrugated volumes track broader goods movement, so a macro slowdown would delay the earnings recovery.
• Input costs and weather disruptions: fiber, OCC, energy, and severe weather (e.g., the Pine Hill, Alabama mill suspension) create near-term operating volatility.
• M&A/restructuring execution: the NORPAC acquisition and the planned separation of North American and European packaging create both value-unlock potential and execution risk.

• Q3 2026 earnings in late October 2026 — evidence of sequential margin expansion and positive free cash flow would be a major positive.
• Containerboard price hike realization in H2 2026, which underpins the recovery narrative.
• Completion of the Carrollton South facility closure and other network-optimization cost savings.
• Progress on separating the North American and European packaging businesses, potentially unlocking value.
• NORPAC acquisition integration adding scale and lower-cost production in the Pacific Northwest.

• Free cash flow is weak: H1 2026 FCF was only ~$87M against heavy capex, and Q2 2026 FCF was -$7M; the $1.81 annual dividend is not currently well covered by FCF.
• The 2025 impairment pattern could repeat if packaging demand or asset values deteriorate further.
• Leverage is meaningful with $8.2B long-term debt and equity already reduced by impairments.
• The DS Smith integration, NORPAC integration, and EMEA separation create genuine operational distraction and execution risk.
• If containerboard pricing recovery stalls, the 29x forward P/E leaves little margin of safety.

IP is not a high-conviction buy right now. It is a cyclical packaging business in the messy middle of a restructuring, and the current price already embeds a recovery that has not yet shown up in free cash flow. The 4.5% dividend adds downside support, but with thin cash conversion and an expensive forward multiple, I would wait for evidence of margin and FCF inflection before treating this as more than a watch item.

Calculated via EV/EBITDA: approximately $3.1B normalized 2027E EBITDA (2026 adjusted run-rate near $2.4B plus containerboard pricing and synergies), a 9.0x mid-cycle multiple, less ~$7.5B net debt, divided by ~529.5M shares, yielding ~$38.55. This is below the $50 analyst consensus because I am not willing to pay a full recovery multiple before cash flow proves the turn.